CRMD
CorMedix Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
3.42
PEG
0.00
P/B
1.37
P/S
1.79
EV/EBITDA
3.39
DCF Value
$2.56
FCF Yield
31.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.5%
Operating Margin
48.2%
Net Margin
52.3%
ROE
58.5%
ROA
39.1%
ROIC
24.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $128.6M | $14.0M | $0.15 |
| FY 2025 | $311.7M | $163.1M | $2.04 |
| Q3 2025 | $104.3M | $108.6M | $1.26 |
| Q2 2025 | $39.7M | $19.8M | $0.28 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.41
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.